Supplementary Material. Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Initially Treated with Baricitinib 4-mg: Week 152 data from BRAVE-AA2

Published: 9 October 2024| Version 1 | DOI: 10.17632/jstxk9gpp3.1
Contributors:
Brett King, Manabu Ohyama, Maryanne Senna, Jerry Shapiro, Yves Dutronc, Frederick Durand, Chunyuan Liu, Guanglei Yu, Jill Kolodsick, Chiara Chiasserini, Najwa Somani, Bianca Maria Piraccini

Description

eTable 1. Percentage of patients with a SALT score ≤20 at each post Week 52 visit eTable 2. Percentage of patients with loss of treatment benefit through Week 152. eTable 3. Baseline demographics and disease measures for patients down-titrated at Week 52 and experienced a loss of treatment benefit vs those who did not experience a loss of treatment benefit. eTable 4. Summary of safety outcomes eFigure 1. A) Sustained response (SALT score ≤20 from Weeks 36 to 52) and B) higher depth of response (SALT score ≤5 at randomized down-titration) were associated with a lower incidence of loss of treatment benefit. eFigure 2. Proportion of patients with a response in A) eyebrow or B) eyelash regrowth from Weeks 52 to 152 for patients down-titrated at Week 52 versus those who remained on their original treatment dose.

Files

Institutions

Yale University School of Medicine

Categories

Clinical Trial, Alopecia, Efficacy Study, Hair Loss, Clinical Outcomes Research, Alopecia Areata, Janus Kinase

Funding

This study was funded by Eli Lilly and Company under license from Incyte.

Licence